Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) shares were down 2.6% during mid-day trading on Monday . The stock traded as low as $18.95 and last traded at $19.37, with a volume of 239,728 shares trading hands. The stock had previously closed at $19.89.

Several research analysts have recently issued reports on BLCM shares. SunTrust Banks Inc. started coverage on shares of Bellicum Pharmacueticals in a report on Thursday, June 2nd. They issued a “buy” rating and a $20.00 price objective for the company. Piper Jaffray Cos. reiterated a “buy” rating on shares of Bellicum Pharmacueticals in a report on Saturday, July 9th. Zacks Investment Research upgraded shares of Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a report on Monday, July 11th. Citigroup Inc. upgraded shares of Bellicum Pharmacueticals from a “neutral” rating to a “buy” rating and set a $24.00 price objective for the company in a report on Tuesday, August 9th. Finally, Jefferies Group increased their price objective on shares of Bellicum Pharmacueticals from $20.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Bellicum Pharmacueticals presently has a consensus rating of “Buy” and a consensus price target of $27.00.

The firm’s market capitalization is $518.78 million. The company’s 50 day moving average is $15.22 and its 200-day moving average is $11.64.

Bellicum Pharmacueticals (NASDAQ:BLCM) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by $0.04. During the same period in the prior year, the company earned ($0.40) EPS. On average, equities research analysts predict that Bellicum Pharmacueticals Inc. will post ($2.32) EPS for the current year.

In related news, COO Annemarie Moseley sold 25,000 shares of Bellicum Pharmacueticals stock in a transaction dated Thursday, June 2nd. The shares were sold at an average price of $13.00, for a total transaction of $325,000.00. Following the completion of the transaction, the chief operating officer now directly owns 18,486 shares of the company’s stock, valued at approximately $240,318. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Ken Moseley sold 15,000 shares of Bellicum Pharmacueticals stock in a transaction dated Thursday, June 2nd. The shares were sold at an average price of $13.00, for a total transaction of $195,000.00. Following the transaction, the vice president now directly owns 15,196 shares of the company’s stock, valued at $197,548. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Bellicum Pharmacueticals stock. Morgan Stanley boosted its stake in shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned 1.61% of Bellicum Pharmacueticals worth $8,653,000 at the end of the most recent quarter.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.